• 3654 Citations
  • 20 h-Index
19972019
If you made any changes in Pure these will be visible here soon.

Research Output 1997 2019

  • 3654 Citations
  • 20 h-Index
  • 54 Article
  • 2 Chapter
  • 1 Comment/debate
  • 1 Review article
Filter
Article
2019
6 Citations (Scopus)

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study

Guarneri, V., Dieci, M. V., Bisagni, G., Frassoldati, A., Bianchi, G. V., De Salvo, G. L., Orvieto, E., Urso, L., Pascual, T., Paré, L., Galván, P., Ambroggi, M., Giorgi, C. A., Moretti, G., Griguolo, G., Vicini, R., Prat, A. & Conte, P. F., Jun 1 2019, In : Annals of Oncology. 30, 6, p. 921-926 6 p., mdz055.

Research output: Contribution to journalArticle

Open Access
letrozole
Hormones
Breast Neoplasms
Therapeutics
Drug Therapy

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Cazzaniga, M. E., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M. R., Airoldi, M., Moretti, G., Ficorella, C., Gianni, L., Michelotti, A., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L. & 31 others, La Verde, N., Bianchi, G. V., Artale, S., Blasi, L., De Laurentiis, M., Atzori, F., Turletti, A., Porpiglia, M., Santini, D., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Giordano, M., Donadio, M., Biganzoli, L., Del Mastro, L., Bisagni, G., Livi, L., Natoli, C., Montemurro, F., Riccardi, F., Romagnoli, E., Marchetti, P., Torri, V., Pronzato, P. & Mustacchi, G., Jan 1 2019, In : Breast Care.

Research output: Contribution to journalArticle

Extravehicular Activity
Breast Neoplasms
Therapeutics
Aromatase Inhibitors
Datasets
Open Access
eribulin
anthracyclines
Triple Negative Breast Neoplasms
taxanes
Catenins
1 Citation (Scopus)

Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles

Vernieri, C., Prisciandaro, M., Milano, M., Cona, M. S., Maggi, C., Brambilla, M., Mennitto, A., Fabbroni, C., Farè, E., Cresta, S., Celio, L., Mariani, G., Bianchi, G., Capri, G. & de Braud, F., Apr 2019, In : Clinical Breast Cancer. 19, 2, p. e306-e318

Research output: Contribution to journalArticle

gemcitabine
Carboplatin
Breast Neoplasms
Safety
Disease-Free Survival

Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study

Mariani, G., Galli, G., Cavalieri, S., Valagussa, P., Bianchi, G. V., Capri, G., Cresta, S., Ferrari, L., Damian, S., Duca, M., de Braud, F. & Moliterni, A., Mar 1 2019, In : Breast Journal. 25, 2, p. 237-242 6 p.

Research output: Contribution to journalArticle

Anthracyclines
Breast Neoplasms
Drug Therapy
Paclitaxel
Methotrexate
2018
1 Citation (Scopus)

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Ancona, C., Airoldi, M., Moretti, G., Ficorella, C., Arcangeli, V., Diodati, L., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L. & 19 others, La Verde, N., Bianchi, G., Artale, S., Blasi, L., Piezzo, M., Atzori, F., Turletti, A., Benedetto, C., Cursano, M. C., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Torri, V. & On behalf of The EVA Study Group, B. O. T. EVA. S. G., Aug 1 2018, In : Oncotarget. 9, 61, p. 31877-31887 11 p.

Research output: Contribution to journalArticle

exemestane
Extravehicular Activity
Breast Neoplasms
Stomatitis
Exanthema

Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer

Lozza, L., Fariselli, L., Sandri, M., Rampa, M., Pinzi, V., De Santis, M. C., Franceschini, M., Trecate, G., Maugeri, I., Fumagalli, L., Bonfantini, F., Bianchi, G., Pignoli, E., De Martin, E. & Agresti, R., Mar 23 2018, In : Radiation Oncology. 13, 1, p. 49

Research output: Contribution to journalArticle

Segmental Mastectomy
Breast
Breast Neoplasms
Cosmetics
Iris

Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., Nusch, A., Sonke, G. S., De La Cruz-Merino, L., Beck, J. T., Pivot, X., Vidam, G., Wang, Y., Lorenc, K. R., Miller, M., Taran, T. & 1 others, Jerusalem, G., 2018, In : Journal of Clinical Oncology. 36, 24, p. 2465-2472 8 p.

Research output: Contribution to journalArticle

The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer

Vernieri, C., Mennitto, A., Prisciandaro, M., Huber, V., Milano, M., Rinaldi, L., Cona, M. S., Maggi, C., Ferrari, B., Manoukian, S., Mariani, G., Bianchi, G., Capri, G., Rivoltini, L. & de Braud, F., Jun 7 2018, In : Scientific Reports. 8, 1, p. 8703

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Platinum
Neutrophils
Blood Platelets
Lymphocytes

Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?

De Santis, M. C., Bonfantini, F., Di Salvo, F., Fiorentino, A., Riboldi, V. M., Di Cosimo, S., Bianchi, G. V., Gennaro, M., Cosentino, V., Sant, M., Pignoli, E., Valdagni, R. & Lozza, L., Jun 2018, In : Clinical Breast Cancer. 18, 3, p. e363-e371

Research output: Contribution to journalArticle

Breast
Radiotherapy
Stroke Volume
Drug Therapy
Skin
2017
5 Citations (Scopus)

Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study

Vernieri, C., Milano, M., Mennitto, A., Maggi, C., Ferrari, B., Rinaldi, L., Mennitto, R., Stefanetti, C., Re, B., Mariani, G., Bianchi, G., Capri, G. & de Braud, F., Sep 1 2017, In : Breast Cancer Research and Treatment. 165, 2, p. 365-373 9 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Retrospective Studies
Disease-Free Survival
Breast Neoplasms
26 Citations (Scopus)

Biomarker analysis of the NeoSphere study: Pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Bianchini, G., Kiermaier, A., Bianchi, G. V., Im, Y. H., Pienkowski, T., Liu, M. C., Tseng, L. M., Dowsett, M., Zabaglo, L., Kirk, S., Szado, T., Eng-Wong, J., Amler, L. C., Valagussa, P. & Gianni, L., Feb 9 2017, In : Breast Cancer Research. 19, 1, 16.

Research output: Contribution to journalArticle

docetaxel
Neoadjuvant Therapy
Biomarkers
Breast Neoplasms
Estrogen Receptors
26 Citations (Scopus)

Biomarker analysis of the NeoSphere study: Pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Bianchini, G., Kiermaier, A., Bianchi, GV., Im, YH., Pienkowski, T., Liu, MC., Tseng, LM., Dowsett, M., Zabaglo, L., Kirk, S., Szado, T., Eng-Wong, J., Amler, LC., Valagussa, P. & Gianni, L., 2017, In : Breast Cancer Research. 19, 6, 16.

Research output: Contribution to journalArticle

docetaxel
Neoadjuvant Therapy
Biomarkers
Breast Neoplasms
Estrogen Receptors
8 Citations (Scopus)

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients

Cazzaniga, M. E., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V. & 20 others, Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, A., Clivio, L., Torri, V., of, O. B. & Gervasi, E., Oct 2017, In : Breast. 35, p. 115-121 7 p.

Research output: Contribution to journalArticle

exemestane
Epidermal Growth Factor
Hormones
Breast Neoplasms
Safety
8 Citations (Scopus)

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Cazzaniga, M. E., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V. & 19 others, Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, A., Clivio, L., Torri, V. & on behalf of, Oct 2017, In : Breast. 35, p. 115-121 7 p.

Research output: Contribution to journalArticle

exemestane
Extravehicular Activity
Epidermal Growth Factor
Clinical Trials
Hormones
8 Citations (Scopus)

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Cazzaniga, M. E., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V. & 20 others, Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, A., Clivio, L., Torri, V., of, O. B. & Group, EVA. S., Oct 1 2017, In : Breast. 35, p. 115-121 7 p.

Research output: Contribution to journalArticle

8 Citations (Scopus)

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, M., Butti, C., Liscia, N., Pogliani, C., Capri, G., Alù, M., Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M. & 49 others, Paternò, E., Guaitoli, G., Ferrarini, I., Gervasi, E., Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, A., Clivio, L. & Torri, V., 2017, In : Breast. 35, p. 115-121 7 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study

Martelli, G., Miceli, R., Folli, S., Guzzetti, E., Chifu, C., Maugeri, I., Ferranti, C., Bianchi, G., Capri, G., Carcangiu, M. L., Paolini, B., Agresti, R., Ferraris, C., Piromalli, D. & Greco, M., Nov 1 2017, In : European Journal of Surgical Oncology. 43, 11, p. 2012-2020 9 p.

Research output: Contribution to journalArticle

Retrospective Studies
Breast Neoplasms
Biopsy
Drug Therapy
Dissection
2016
195 Citations (Scopus)

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial

Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S. A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V., Douthwaite, H., Ross, G. & Valagussa, P., 2016, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Breast Neoplasms
docetaxel
Disease-Free Survival
pertuzumab
Trastuzumab

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial

Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S. A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V. A., Douthwaite, H., Ross, G. & Valagussa, P., 2016, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Breast Neoplasms
docetaxel
Disease-Free Survival
pertuzumab
Trastuzumab

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

Gianni, L., Pienkowski, T., Im, Y-H., Tseng, L-M., Liu, M-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S-A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V., Douthwaite, H., Ross, G. & Valagussa, P., Jun 1 2016, In : The Lancet Oncology. 17, 6, p. 791 - 800 10 p.

Research output: Contribution to journalArticle

Breast Neoplasms
docetaxel
Disease-Free Survival
pertuzumab
Trastuzumab
22 Citations (Scopus)

Current challenges in HER2-positive breast cancer

Puglisi, F., Fontanella, C., Amoroso, V., Bianchi, G. V., Bisagni, G., Falci, C., Fontana, A., Generali, D., Gianni, L., Grassadonia, A., Moscetti, L., Portarena, I., Rossi, E. & Marchetti, P., Feb 1 2016, In : Critical Reviews in Oncology/Hematology. 98, p. 211-221 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Heart Diseases
Safety
Neoplasms

Current challenges in HER2-positive breast cancer

Puglisi, F., Fontanella, C., Amoroso, V., Bianchi, G. V., Bisagni, G., Falci, C., Fontana, A., Generali, D., Gianni, L., Grassadonia, A., Moscetti, L., Portarena, I., Rossi, E. & Marchetti, P., Feb 1 2016, In : Critical Reviews in Oncology/Hematology. 98, p. 211-221 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Heart Diseases
Safety
Neoplasms

Current challenges in HER2-positive breast cancer

Puglisi, F., Fontanella, C., Amoroso, V., Bianchi, G. V., Bisagni, G., Falci, C., Fontana, A., Generali, D., Gianni, L., Grassadonia, A., Moscetti, L., Portarena, I., Rossi, E. & Marchetti, P., Feb 1 2016, In : Critical Reviews in Oncology/Hematology. 98, p. 211-221 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Heart Diseases
Safety
Neoplasms

Current challenges in HER2-positive breast cancer

Puglisi, F., Fontanella, C., Amoroso, V., Bianchi, G. V., Bisagni, G., Falci, C., Fontana, A., Generali, D., Gianni, L., Grassadonia, A., Moscetti, L., Portarena, I., Rossi, E. & Marchetti, P., Feb 1 2016, In : Critical Reviews in Oncology/Hematology. 98, p. 211-221 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Heart Diseases
Safety
Neoplasms
Propensity Score
Nipples
Mastectomy
Safety
Drug Therapy
11 Citations (Scopus)

Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy

De Santis, M. C., Bonfantini, F., Di Salvo, F., Dispinzieri, M., Mantero, E., Soncini, F., Baili, P., Sant, M., Bianchi, G., Maggi, C., Di Cosimo, S., Agresti, R., Pignoli, E., Valdagni, R. & Lozza, L., Oct 1 2016, In : Breast. 29, p. 90-95 6 p.

Research output: Contribution to journalArticle

Breast
Radiotherapy
Breast Neoplasms
Drug Therapy
Fibrosis

Pitfalls in oncology: A unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer

Gelsomino, F., Castellani, M. R., Marchianò, A., Duca, M., Mariani, P., Aliberti, G., Maccauro, M., Duranti, L., Capri, G., De Braud, F. G. & Bianchi, G. V., Jun 1 2016, In : Journal of Thoracic Disease. 8, 6, p. E403-E407

Research output: Contribution to journalArticle

Splenosis
Thorax
Breast Neoplasms
Neoplasms
Unnecessary Procedures
11 Citations (Scopus)

Predictive biomarkers in the treatment of HER2-positive breast cancer: An ongoing challenge

Triulzi, T., Bianchi, G. V. & Tagliabue, E., Jun 1 2016, In : Future Oncology. 12, 11, p. 1413-1428 16 p.

Research output: Contribution to journalArticle

Biomarkers
Breast Neoplasms
Neoplasms
Receptor Protein-Tyrosine Kinases
Disease-Free Survival
15 Citations (Scopus)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition

Di Modica, M., Sfondrini, L., Regondi, V., Varchetta, S., Oliviero, B., Mariani, G., Bianchi, G. V., Generali, D., Balsari, A., Triulzi, T. & Tagliabue, E., 2016, In : Oncotarget. 7, 1, p. 255-265 11 p.

Research output: Contribution to journalArticle

Antibody-Dependent Cell Cytotoxicity
Taxoids
Natural Killer Cells
NK Cell Lectin-Like Receptor Subfamily K
docetaxel

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition

Di Modica, M., Sfondrini, L., Regondi, V., Varchetta, S., Oliviero, B., Mariani, G., Bianchi, G. V., Generali, D., Balsari, A., Triulzi, T. & Tagliabue, E., 2016, In : Oncotarget. 7, 1, p. 255-265 11 p.

Research output: Contribution to journalArticle

Antibody-Dependent Cell Cytotoxicity
Taxoids
Natural Killer Cells
NK Cell Lectin-Like Receptor Subfamily K
docetaxel
2015
21 Citations (Scopus)
Residual Neoplasm
Positron-Emission Tomography
Breast Neoplasms
Drug Therapy
Cohort Studies
13 Citations (Scopus)
Circulating Neoplastic Cells
Tumors
Cells
Breast Neoplasms
Neoplasms
2 Citations (Scopus)

Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: Management considerations

Del Mastro, L., Cazzaniga, M., Solidoro, P., Generali, D., Bianchi, G., Testore, F. & De Placido, S., Aug 1 2015, In : Future Oncology. 11, 16, p. 2251-2254 4 p.

Research output: Contribution to journalArticle

63 Citations (Scopus)

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

Bianchini, G., Pusztai, L., Pienkowski, T., Im, Y. H., Bianchi, G. V., Tseng, L. M., Liu, M. C., Lluch, A., Galeota, E., Magazzù, D., de la Haba-Rodríguez, J., Oh, D. Y., Poirier, B., Pedrini, J. L., Semiglazov, V., Valagussa, P. & Gianni, L., Dec 1 2015, In : Annals of Oncology. 26, 12, p. 2429-2436 8 p.

Research output: Contribution to journalArticle

Breast
Interferons
Genes
Therapeutics
docetaxel
2 Citations (Scopus)

Prognosis of women with early breast cancer and PIK3CA mutations

Di Cosimo, S., Bianchi, G. V., Bregni, G. & de Braud, F., Jun 1 2015, In : Breast. 24, 3, p. 283-284 2 p.

Research output: Contribution to journalArticle

2014
37 Citations (Scopus)

Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98)

Agresti, R., Martelli, G., Sandri, M., Tagliabue, E., Carcangiu, M. L., Maugeri, I., Pellitteri, C., Ferraris, C., Capri, G., Moliterni, A., Bianchi, G., Mariani, G., Trecate, G., Lozza, L., Langer, M., Rampa, M., Gennaro, M., Greco, M., Menard, S. & Pierotti, M. A., Mar 15 2014, In : Cancer. 120, 6, p. 885-893 9 p.

Research output: Contribution to journalArticle

Lymph Node Excision
Dissection
Randomized Controlled Trials
Breast Neoplasms
Arm
2 Citations (Scopus)

Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: Results and clinical implications after eight-years follow-up

Agresti, R., Crippa, F., Sandri, M., Martelli, G., Tagliabue, E., Alessi, A., Pellitteri, C., Maccauro, M., Maugeri, I., Barbara, P., Rampa, M., Moscaroli, A., Ferraris, C., Carcangiu, M. L., Bianchi, G., Greco, M. & Bombardieri, E., 2014, In : Breast. 23, 4, p. 334-340 7 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Population
Biopsy
Survival
cyhalothrin
2013

Lapatinib and letrozole as first-line therapy for metastatic breast cancer: Case report of bone metastasis 18 years later

Mariani, G., Ricchini, F., Sica, L. & Bianchi, G. V., Nov 2013, In : Tumori. 99, 6

Research output: Contribution to journalArticle

letrozole
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Progesterone Receptors
4 Citations (Scopus)
Breast Neoplasms
Therapeutics
lapatinib
Trastuzumab
Capecitabine
250 Citations (Scopus)

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., Chu, Y. W. & Perez, E. A., Mar 20 2013, In : Journal of Clinical Oncology. 31, 9, p. 1157-1163 7 p.

Research output: Contribution to journalArticle

docetaxel
Breast Neoplasms
Disease-Free Survival
Safety
Therapeutics
2012
1110 Citations (Scopus)

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial

Gianni, L., Pienkowski, T., Im, Y. H., Roman, L., Tseng, L. M., Liu, M. C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S. A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G., Szado, T., Ratnayake, J., Ross, G. & Valagussa, P., Jan 2012, In : The Lancet Oncology. 13, 1, p. 25-32 8 p.

Research output: Contribution to journalArticle

docetaxel
Breast Neoplasms
Safety
pertuzumab
Trastuzumab
171 Citations (Scopus)

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer

Corteś, J., Fumoleau, P., Bianchi, G., Petrella, T. M., Gelmon, K., Pivot, X., Verma, S., Albanell, J., Conte, P., Lluch, A., Salvagni, S., Servent, V., Gianni, L., Scaltriti, M., Ross, G. A., Dixon, J., Szado, T. & Baselga, J., May 10 2012, In : Journal of Clinical Oncology. 30, 14, p. 1594-1600 7 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Disease Progression
Trastuzumab
human ERBB2 protein
2010
119 Citations (Scopus)

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

Gianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P. L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J. C., Hersberger, V. & Baselga, J., Mar 1 2010, In : Journal of Clinical Oncology. 28, 7, p. 1131-1137 7 p.

Research output: Contribution to journalArticle

Dimerization
Multicenter Studies
Breast Neoplasms
Safety
human ERBB2 protein
470 Citations (Scopus)

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., Fumoleau, P. & Gianni, L., Mar 1 2010, In : Journal of Clinical Oncology. 28, 7, p. 1138-1144 7 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Disease Progression
Monoclonal Antibodies
Safety
2009
91 Citations (Scopus)

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

Bianchi, G., Loibl, S., Zamagni, C., Salvagni, S., Raab, G., Siena, S., Laferriere, N., Peña, C., Lathia, C., Bergamini, L. & Gianni, L., 2009, In : Anti-Cancer Drugs. 20, 7, p. 616-624 9 p.

Research output: Contribution to journalArticle

Multicenter Studies
Breast Neoplasms
sorafenib
Drug Therapy
Exanthema
504 Citations (Scopus)

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

Baselga, J., Semiglazov, V., Van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., Campone, M., Kubista, E., Greil, R., Bianchi, G., Steinseifer, J., Molloy, B., Tokaji, E., Gardner, H., Phillips, P., Stumm, M., Lane, H. A., Dixon, J. M., Jonat, W. & Rugo, H. S., Jun 1 2009, In : Journal of Clinical Oncology. 27, 16, p. 2630-2637 8 p.

Research output: Contribution to journalArticle

letrozole
Estrogen Receptors
Placebos
Breast Neoplasms
S 6
2007
128 Citations (Scopus)

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale

Cavaletti, G., Frigeni, B., Lanzani, F., Piatti, M., Rota, S., Briani, C., Zara, G., Plasmati, R., Pastorelli, F., Caraceni, A., Pace, A., Manicone, M., Lissoni, A., Colombo, N., Bianchi, G. & Zanna, C., Sep 2007, In : Journal of the Peripheral Nervous System. 12, 3, p. 210-215 6 p.

Research output: Contribution to journalArticle

National Cancer Institute (U.S.)
Drug Therapy
Antineoplastic Agents
2005
108 Citations (Scopus)

Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine

Bianchi, G., Vitali, G., Caraceni, A., Ravaglia, S., Capri, G., Cundari, S., Zanna, C. & Gianni, L., Aug 2005, In : European Journal of Cancer. 41, 12, p. 1746-1750 5 p.

Research output: Contribution to journalArticle

Acetylcarnitine
Sural Nerve
Peroneal Nerve
Nausea
TP protocol